ARCC vs. AZN
ARCC (Ares Capital Corporation) and AZN (AstraZeneca PLC) are both stocks. ARCC operates in Asset Management (Financial Services), while AZN operates in Drug Manufacturers - General (Healthcare). Over the past 10 years, ARCC returned 13.20%/yr vs 15.97%/yr for AZN. At a 0.26 correlation, their price movements are largely independent.
Performance
ARCC vs. AZN - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ARCC achieves a -2.20% return, which is significantly lower than AZN's -0.75% return. Over the past 10 years, ARCC has underperformed AZN with an annualized return of 13.20%, while AZN has yielded a comparatively higher 15.97% annualized return.
ARCC
- 1D
- 1.00%
- 1M
- 1.90%
- YTD
- -2.20%
- 6M
- -2.87%
- 1Y
- -3.87%
- 3Y*
- 10.27%
- 5Y*
- 9.04%
- 10Y*
- 13.20%
AZN
- 1D
- -1.94%
- 1M
- -1.56%
- YTD
- -0.75%
- 6M
- 1.57%
- 1Y
- 23.46%
- 3Y*
- 8.94%
- 5Y*
- 11.28%
- 10Y*
- 15.97%
ARCC vs. AZN - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
ARCC Ares Capital Corporation | -2.20% | 1.07% | 19.78% | 20.03% | -3.84% | 36.14% | 0.86% | 31.30% | 8.81% | 4.50% |
AZN AstraZeneca PLC | -0.75% | 43.30% | -0.62% | 1.44% | 19.14% | 19.66% | 3.12% | 35.68% | 13.86% | 33.10% |
Correlation
The correlation between ARCC and AZN is 0.06, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.06 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.12 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.17 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.17 |
Correlation (All Time) Calculated using the full available price history since Oct 6, 2004 | 0.26 |
Over the past year, the correlation between ARCC and AZN has dropped to 0.06 - well below their long-term average of 0.26, suggesting their price drivers have been diverging.
Fundamentals
ARCC:
$13.83B
AZN:
$279.03B
ARCC:
$1.63
AZN:
$6.66
ARCC:
11.81
AZN:
26.85
ARCC:
1.77
AZN:
0.04
ARCC:
5.16
AZN:
4.62
ARCC:
0.98
AZN:
5.90
ARCC:
$2.63B
AZN:
$60.44B
ARCC:
$1.86B
AZN:
$49.37B
ARCC:
$2.05B
AZN:
$20.47B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ARCC vs. AZN — Risk / Return Rank
ARCC
AZN
ARCC vs. AZN - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Ares Capital Corporation (ARCC) and AstraZeneca PLC (AZN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ARCC | AZN | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.16 | ||
| Sortino ratioReturn per unit of downside risk | -1.77 | ||
| Omega ratioGain probability vs. loss probability | 0.97 | 1.17 | -0.20 |
| Calmar ratioReturn relative to maximum drawdown | -0.26 | 1.47 | -1.73 |
| Martin ratioReturn relative to average drawdown | -0.47 | 3.82 | -4.30 |
Loading charts...
Drawdowns
ARCC vs. AZN - Drawdown Comparison
The maximum ARCC drawdown since its inception was -79.36%, which is greater than AZN's maximum drawdown of -48.94%. Use the drawdown chart below to compare losses from any high point for ARCC and AZN.
Loading charts...
Drawdown Indicators
| ARCC | AZN | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -79.36% | -48.94% | -30.42% |
Max Drawdown (1Y)Largest decline over 1 year | -19.35% | -15.43% | -3.92% |
Max Drawdown (3Y)Largest decline over 3 years | -19.35% | -27.87% | +8.52% |
Max Drawdown (5Y)Largest decline over 5 years | -21.76% | -27.87% | +6.11% |
Max Drawdown (10Y)Largest decline over 10 years | -56.77% | -27.87% | -28.90% |
Current DrawdownCurrent decline from peak | -10.98% | -14.25% | +3.27% |
Average DrawdownAverage peak-to-trough decline | -9.10% | -11.37% | +2.27% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 10.68% | 5.99% | +4.69% |
Volatility
ARCC vs. AZN - Volatility Comparison
The current volatility for Ares Capital Corporation (ARCC) is 3.72%, while AstraZeneca PLC (AZN) has a volatility of 7.95%. This indicates that ARCC experiences smaller price fluctuations and is considered to be less risky than AZN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ARCC | AZN | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 3.72% | 7.95% | -4.23% |
Volatility (6M)Calculated over the trailing 6-month period | 14.83% | 17.74% | -2.91% |
Volatility (1Y)Calculated over the trailing 1-year period | 18.48% | 25.76% | -7.28% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 19.96% | 24.03% | -4.07% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 25.58% | 24.93% | +0.65% |
Dividends
ARCC vs. AZN - Dividend Comparison
ARCC's dividend yield for the trailing twelve months is around 9.97%, more than AZN's 2.98% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
ARCC Ares Capital Corporation | 7.48% | 9.49% | 8.77% | 9.59% | 10.12% | 7.65% | 9.47% | 9.01% | 9.88% | 9.67% | 9.22% | 11.02% |
AZN AstraZeneca PLC | 2.98% | 1.70% | 2.27% | 2.15% | 2.12% | 2.35% | 2.80% | 2.81% | 3.69% | 3.95% | 5.01% | 4.06% |
Financials
ARCC vs. AZN - Financials Comparison
This section allows you to compare key financial metrics between Ares Capital Corporation and AstraZeneca PLC. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
ARCC vs. AZN - Profitability Comparison
ARCC - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Ares Capital Corporation reported a gross profit of 550.00M and revenue of 763.00M. Therefore, the gross margin over that period was 72.1%.
AZN - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, AstraZeneca PLC reported a gross profit of 12.61B and revenue of 15.29B. Therefore, the gross margin over that period was 82.5%.
ARCC - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Ares Capital Corporation reported an operating income of 404.00M and revenue of 763.00M, resulting in an operating margin of 53.0%.
AZN - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, AstraZeneca PLC reported an operating income of 4.25B and revenue of 15.29B, resulting in an operating margin of 27.8%.
ARCC - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Ares Capital Corporation reported a net income of 92.00M and revenue of 763.00M, resulting in a net margin of 12.1%.
AZN - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, AstraZeneca PLC reported a net income of 3.08B and revenue of 15.29B, resulting in a net margin of 20.2%.
Frequently Asked Questions
ARCC and AZN have a correlation of 0.06, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
AZN has higher volatility (7.95%) compared to ARCC (3.72%). In terms of maximum drawdown, ARCC dropped -79.36% vs AZN's -48.94%.
AZN currently has the higher Sharpe Ratio (0.88 vs -0.27), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ARCC and AZN
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer